An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

NCT01677455 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
HER-2 Positive Breast Cancer
Triple Negative Breast Cancer
ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment

Interventions

DRUG: ganetespib

Sponsor

Synta Pharmaceuticals Corp.